Navigation Links
Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate)

Results show risk of heart attack comparable to two widely used diabetes medicines

LONDON, June 6, 2007- A study of more than 33,000 type 2 diabetes patients in a real-world setting was published today. This study shows that the incidence of hospitaliations for heart attack, and/or for a surgery known as coronary revascularization for patients on Avandia is the same as for other diabetes treatments. The study results were released in a paper titled “Coronary Heart Disease Outcomes in Patients Receiving Antidiabetic Agents” in Pharmacoepidemiology and Drug Safety.

These data, also described in a letter published online last week (May 30, 2007) in the medical journal The Lancet, are further evidence that the ischemic cardiovascular safety of Avandia is comparable to the most commonly used type 2 diabetes treatments – as evidenced in long-term prospective trials, such as ADOPT and DREAM. The findings conflict with a hypothesis generated by the recently published meta-analysis in the New England Journal of Medicine that raised concerns regarding ischemic risks with Avandia.

Based on an observational cohort study from a large U.S.managed-care database, this research was commissioned by GlaxoSmithKline as part of its commitment to the ongoing monitoring and assessment of the safety of Avandia. The study was designed to compare the risk of heart attack and coronary revascularization in type 2 diabetes patients taking Avandia, metformin or sulfonylurea – either alone, as two medicines combined and in combination with insulin. The study populations were matched to ensure that the cohort groups were similar in terms of their baseline risk factors for cardiovascular disease. Patients were followed for an avera ge of slightly over a year.

The results demonstrate that:

• there was no difference in the overall incidence of heart attack and coronary revascularization with Avandia-containing therapies (1.75 events per 100 person-years) versus non-Avandia containing therapies (1.76 events per 100 person-years) (hazard ratio 0.93, 95% CI 0.80 – 1.10);

• there was no difference in the risk of either heart attack (hazard ratio 0.92, 95% CI 0.73 – 1.16) or coronary revascularization (hazard ratio 0.94, 95% CI 0.79 – 1.12) - with Avandia-containing therapies compared to non-Avandia containing therapies;

• there was no difference in the risk of the composite outcome with Avandia monotherapy compared to metformin monotherapy (hazard ratio 1.07, 95% CI: 0.85 – 1.34), and similarly with Avandia monotherapy compared to sulfonylurea monotherapy (hazard ratio 0.82, 95% CI: 0.67 – 1.02);

• there was no difference in the risk of composite outcome with Avandia in combination with insulin therapy compared to other oral antidiabetic agents in combination with insulin (hazard ratio 0.88, 95% CI: 0.59 – 1.32).

Avandia is an effective medicine that is an important treatment for millions of patients who are using it to manage their diabetes, a disease with potentially devastating consequences if left unmanaged.

Glossary of Terms:

Coronary revascularization - the process of restoring blood flow of oxygen to the heart via a surgical procedure to bypass blockages or obstructions in the coronary arteries

Cohort - a group within a given population followed over a period of time

CI (con fidence interval) - quantifies the range that covers the mean via an upper and lower limit for the actual value

Patient year - the cumulative amount of time that a patient has taken a particular medicine as measured in years.

Enquiries:

UK Media enquiries:

Philip Thomson

(020) 8047 5502

Joss Mathieson

(020) 8047 5502

Gwenan White

(020) 8047 5502

US Media enquiries:

Nancy Pekarek

(215) 751 7709

Alice Hunt

(215) 751 7709

Mary Anne Rhyne

(919) 483 2839

European Analyst/Investor enquiries:

Anita Kidgell

(020) 8047 5542

David Mawdsley

(020) 8047 5564

Sally Ferguson

(020) 8047 5543

US Analyst/ Investor enquiries:

Frank Murdolo

(215) 751 7002

Tom Curry

(215) 751 5419


'"/>




Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
3. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
4. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
5. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
6. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
7. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
8. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
9. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
(Date:5/24/2016)...   , ... primären Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung ... plus guter , Reinigung des ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... von der MORA-Studie der Phase III für NER1006 ...
(Date:5/24/2016)... , May 24, 2016 ... solutions for the healthcare sector, has been named the Coretex ... Hi-Tech Awards 2016. Dr Bruce Davey , ... for our team.  It,s really good to be recognised for ... internationally. Our products are used in 35 countries around the ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare industry ... for its inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., ... health of America’s healthcare providers. , The conference was highlighted by the announcement ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... has a significant negative impact on long-term patient survival, reports a team of ... published online this week in the Journal of Thoracic and Cardiovascular Surgery, provide ...
(Date:5/26/2016)... ... , ... An April Gallup survey found rising health care costs to be ... Health Senior Living (SHSL) may not share those same worries thanks to a ... the year, while holding the line on increasing their contributions, including premiums, deductibles and ...
(Date:5/26/2016)... Fla. (PRWEB) , ... May 26, 2016 , ... The ... (AHEC) to host a six-week smoking cessation class starting June 6 at their clinic ... website, http://www.gnahec.org . , Additionally, the Lung Institute has created a free downloadable ...
(Date:5/26/2016)... Scotch Plains, NJ (PRWEB) , ... May 26, ... ... year being recognized as an NJ Top Doc! Along with his wonderful accolades ... to excellence in podiatry. Congratulations, Dr. Batelli! , Dr. Eugene Batelli is ...
Breaking Medicine News(10 mins):